Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9927985 | 0.91 | CASR (0.36) | CASRUSP2KDM4EHTTALDH1A1 | |
| SCHEMBL62323 | 0.89 | CASR (0.34) | CASRUSP2KDM4EHTTALDH1A1 | |
| SCHEMBL9928022 | 0.89 | MMP9 (0.39) | CASRUSP2KDM4EHTT | |
| SCHEMBL9927988 | 0.89 | MMP9 (0.39) | CASRUSP2KDM4EHTT | |
| SCHEMBL9927992 | 0.89 | MMP9 (0.39) | CASRUSP2KDM4EHTT | |
| SCHEMBL9928006 | 0.89 | USP2 (0.39) | USP2KDM4EHTTALDH1A1LMNA | |
| SCHEMBL15218997 | 0.89 | KDM4E (0.40) | CASRUSP2KDM4EHTTALDH1A1 | |
| SCHEMBL9928014 | 0.86 | USP2 (0.31) | USP2KDM4EHTTALDH1A1 | |
| SCHEMBL5051862 | 0.86 | USP2 (0.45) | CASRUSP2KDM4EHTTLMNA | |
| SCHEMBL18102292 | 0.85 | HTT (0.34) | CASRUSP2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944534-B2 | Reducing aluminosilicate scale in the Bayer process | ECOLAB USA INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170050861-A1 | Reducing Aluminosilicate Scale in the Bayer Process | NALCO COMPANY (US) | 2017-02-23 | — | — | US | disclosed |
| US-9487408-B2 | Reducing aluminosilicate scale in the bayer process | NALCO COMPANY (US) | 2016-11-08 | — | — | US | disclosed |
| US-9487408-B2 | Reducing aluminosilicate scale in the bayer process | NALCO COMPANY (US) | 2016-11-08 | — | — | US | disclosed |
| US-8889096-B2 | Reducing aluminosilicate scale in the bayer process | NALCO COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889096-B2 | Reducing aluminosilicate scale in the bayer process | NALCO COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| WO-2013126683-A1 | REDUCING ALUMINOSILICATE SCALE IN THE BAYER PROCESS | NALCO COMPANY (US) | 2013-08-29 | — | — | WO | disclosed |
| US-20120148462-A1 | REDUCING ALUMINOSILICATE SCALE IN THE BAYER PROCESS | ECOLAB USA INC. | 2012-06-14 | — | — | US | disclosed |
| US-20120148462-A1 | REDUCING ALUMINOSILICATE SCALE IN THE BAYER PROCESS | ECOLAB USA INC. | 2012-06-14 | — | — | US | disclosed |
| US-20110212006-A1 | REDUCING ALUMINOSILICATE SCALE IN THE BAYER PROCESS | ECOLAB USA INC. | 2011-09-01 | — | — | US | disclosed |
| US-20110212006-A1 | REDUCING ALUMINOSILICATE SCALE IN THE BAYER PROCESS | ECOLAB USA INC. | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050861-A1 | Reducing Aluminosilicate Scale in the Bayer Process | DSP, SOST, SORD | CASR 612/4885USP2 2966/4885KDM4E 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.